Clinical Trial

A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)

Study acronym: SurfSubQ
Recruiting
View on ClinicalTrials.gov →
Summary
The main purpose of the study is to evaluate participant satisfaction after administration of ocrelizumab subcutaneously (SC) after 12 months using the therapy administration satisfaction questionnaire subcutaneous (TASQ-SC).
Protocol Amendment History 4 changes
critical Primary endpoint(s) modified 2026-07-16
notable Trial sites expanded: 84 -> 90 locations 2026-05-28
notable Trial sites expanded: 78 -> 84 locations 2026-04-28
notable Trial sites expanded: 74 -> 78 locations 2026-03-31
Trial Details
NCT Number NCT06780150
Lead Sponsor Hoffmann-La Roche
Conditions Multiple Sclerosis
Enrollment 842 participants
Start Date 2024-09-26
Primary Completion 2028-03-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-15